Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
AI 90-DAY FORECAST
NEUTRAL SIGNAL
██.█% Sign up free to reveal

Nuo Therapeutics, Inc. (AURX) AI Forecast

Our AI analyzed Nuo Therapeutics, Inc.. Create a free account and follow it to see the 90-day price prediction.

Free account • 30-day free trial

$AURX Neutral Signal Full forecast available

Nuo Therapeutics, Inc. (AURX) Stock Forecast 2025


Nuo Therapeutics, Inc. (AURX) AI Stock Price Forecast & Investment Analysis

Nuo Therapeutics, Inc. Stock Price Chart and Technical Analysis

Loading chart...

Nuo Therapeutics, Inc. (AURX) - Comprehensive Stock Analysis & Investment Research

Deep dive into Nuo Therapeutics, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on July 28, 2026, 9:19 a.m. (UTC)

Nuo Therapeutics, Inc. Investment Summary

When evaluating whether Nuo Therapeutics, Inc. (AURX) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Nuo Therapeutics, Inc. (AURX) operates within the Industrial Applications and Services sector, specifically in the Surgical & Medical Instruments & Apparatus industry. . With a market capitalization of $49 million, the company is a small-cap stock that may offer higher growth potential but also carries higher volatility.

Financial Performance Analysis

Our comprehensive financial analysis covers Nuo Therapeutics, Inc.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Nuo Therapeutics, Inc. along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Nuo Therapeutics, Inc. is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Nuo Therapeutics, Inc.

Sign Up Free
Corporate Identity

Nuo Therapeutics, Inc. (Stock Symbol: AURX) is a prominent company operating within the Industrial Applications and Services sector, with a specific focus on the Surgical & Medical Instruments & Apparatus industry. The company's shares are publicly traded on the OTC exchange.

Leadership & Workforce

Detailed information about Nuo Therapeutics, Inc.'s leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Nuo Therapeutics, Inc....

Sector & Industry Analysis

In-depth sector dynamics and industry context for Nuo Therapeutics, Inc....

Unlock Full Company Profile

Get complete details about Nuo Therapeutics, Inc.

Sign Up Free
Revenue & Growth Analysis

Nuo Therapeutics, Inc. generates annual revenues of $4 million , representing an emerging company in its growth phase.

Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Nuo Therapeutics, Inc....

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Nuo Therapeutics, Inc....

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Nuo Therapeutics, Inc....

Unlock Financial Analysis

Get complete financial metrics for Nuo Therapeutics, Inc.

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Nuo Therapeutics, Inc.'s AI Price Forecast

Join 10,000+ investors using our 67%+ accurate AI predictions

4,000+ Stocks Analyzed
67%+ Accuracy Rate
Daily Updates
Start 30-Day Free Trial

30-day free trial • Cancel anytime

Strategic Market Position

Nuo Therapeutics, Inc. strategically competes in the highly dynamic Surgical & Medical Instruments & Apparatus marketplace. As a small-cap company, it represents an emerging market participant with potentially significant growth opportunities. Small-caps often offer greater growth potential as they capture market share and scale their operations, though this comes with higher risk and volatility. Success at this stage can lead to substantial returns for early investors who identify winning business models.

Industry Competitive Landscape

Nuo Therapeutics, Inc. competes within the Industrial Applications and Services sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency

The company currently shows negative free cash flow of $-2 million . Negative free cash flow may reflect heavy investment in growth, working capital needs, or operational challenges. This is common for high-growth companies investing aggressively but warrants attention for mature businesses.

Margin & Pricing Power Analysis

The company maintains a 53.5% gross margin indicating healthy pricing power relative to direct production costs. This margin level suggests the company has successfully differentiated its products or services, allowing it to command prices meaningfully above input costs. Maintaining these margins requires ongoing investment in brand, technology, or other differentiating factors.

Operating margin of -98.6% demonstrates how efficiently the company converts revenues into operating profits after accounting for all operating expenses including research and development, sales and marketing, and general administrative costs. Operating margin compression relative to gross margin suggests high operating expenses that may warrant efficiency improvements or reflect necessary growth investments.

Asset Utilization Efficiency

Asset turnover ratio of 2.12x indicates exceptional efficiency in utilizing company assets to generate revenue. High asset turnover is characteristic of retail, distribution, or service businesses that operate with relatively lean asset bases. This efficiency translates to higher returns on invested capital when combined with reasonable margins.

Financial Strength & Leverage

Current ratio of 1.11 suggests tight liquidity where current assets just cover current liabilities. This may be efficient but leaves limited cushion for unexpected needs.

Nuo Therapeutics, Inc. (AURX) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Nuo Therapeutics, Inc. stock analysis.

Deep dive into Nuo Therapeutics, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Nuo Therapeutics, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Nuo Therapeutics, Inc.:

Market Cap $49M
Revenue/Share $0.09
FCF/Share $-0.04
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Nuo Therapeutics, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Nuo Therapeutics, Inc.: An ROE of 636.4% demonstrates excellent shareholder value creation.

ROE 636.4%
ROA -452.6%
ROIC -1888.0%
Gross Margin 53.5%
Operating Margin -98.6%
Net Margin -79.8%
EBT Margin -79.4%
Tax Rate -0.5%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Nuo Therapeutics, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Nuo Therapeutics, Inc.: A current ratio of 1.11 shows adequate liquidity.

Current Ratio 1.11x
Quick Ratio 0.93x
D/E Ratio -2.41x
Financial Leverage -1.41x
Interest Coverage -373.0x
Working Capital $150K
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Nuo Therapeutics, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Nuo Therapeutics, Inc.: Free cash flow of $-2M indicates cash challenges that need attention.

Operating Cash Flow -$11M
Free Cash Flow -$2M
Capital Spending $9M
FCF/Sales -41.1%
CapEx/Sales 216.0%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Nuo Therapeutics, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Nuo Therapeutics, Inc.: An asset turnover of 2.12x demonstrates efficient asset utilization.

Asset Turnover 2.12x
Receivables Turnover 4.7x
Inventory Turnover 20.7x
Fixed Assets Turnover 12.0x
Days Sales Outstanding 77 days
Days Inventory 18 days
Payables Period 27 days
Cash Conversion Cycle 67 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Nuo Therapeutics, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Nuo Therapeutics, Inc.: With annual revenue of $4M, Nuo Therapeutics, Inc. represents a smaller but potentially high-growth operation.

Income Statement
Total Revenue $4M
Operating Income -$10M
Net Income -$8M
R&D Expense $410K
Cost of Goods Sold $5M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 2%
Cash & Short-term Investments 0%
Total Liabilities 3%
Short-term Debt 1%
Accounts Receivable 1%
Inventory 0%
Dividend & Shareholder Information
Shares Outstanding 48M
Growth Metrics (YoY)
Net Income Growth -79.8%

Latest Nuo Therapeutics, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Nuo Therapeutics, Inc. (AURX) stock price and investment outlook.

📰 Loading...

Nuo Therapeutics, Inc. Competitors & Peer Analysis - Industrial Applications and Services Sector

Comparative analysis of Nuo Therapeutics, Inc. against industry peers and competitors in the Industrial Applications and Services sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
ADGM ██% $11M x 1.9x
AEMD ██% $1M x 0.3x
ALUR ██% $6M x x
AMIX ██% $2M x 0.3x
ANGO ██% $570M x 3.3x
ANIK ██% $201M x 1.5x
AORT ██% $1.25B 107.3x 2.8x
APYX ██% $163M x 12.7x
ARAY ██% $27M x 0.6x
ATEC ██% $1.33B x x
ATRC ██% $1.90B 182.0x 3.7x
AURX ██% $49M x x
BAX ██% $12.02B x 2.0x
BBNX ██% $713M x 2.6x
BDX ██% $43.79B 38.5x 1.8x
BEAT ██% $29M x 45.9x
BJDX ██% $1M x 0.3x
BSX ██% $67.58B 19.0x 2.6x
BTCY ██% $2M x x
BVS ██% $838M 29.4x 4.4x
BWAY ██% $632M x x
CARL ██% $311M x 3.4x
CERS ██% $596M x 8.8x
CLPT ██% $438M x 23.2x
CODX ██% $7M x 0.5x
CTSO ██% $23M x 10.3x
CVRX ██% $129M x 4.4x
DCTH ██% $412M 733.5x 3.7x
DRIO ██% $55M x 0.9x
DRTS ██% $1.07B x 13.9x
DXCM ██% $28.31B 30.4x 9.6x
EBRCZ ██% $137M x 14.4x
EMBC ██% $204M 1.8x x
FEMY ██% $9M x 1.3x
FOFA ██% $27M 173.9x 28.2x
GCTK ██% $2M x x
GIPL ██% $170K x 0.3x
GKOS ██% $8.87B x 13.2x
GMED ██% $10.59B 18.1x 2.2x
GUTS ██% $127M x 6.0x
HAE ██% $3.62B 37.2x 4.5x
HRGN ██% $18M x 200.7x
HTFL ██% $2.18B x 7.7x
IART ██% $1.50B x 1.4x
ICCM ██% $10M x 1.1x
ICUI ██% $4.04B 87.1x 1.9x
IDXG ██% $43M 1.8x 1.9x
INBS ██% $4M x 0.5x
INSP ██% $1.47B 11.2x 1.9x
IRMD ██% $1.22B 51.5x 12.3x
IRTC ██% $3.68B x 22.9x
IVF ██% $2M x 0.1x
KIDS ██% $469M x 1.4x
KMTS ██% $1.33B x 5.1x
KRMD ██% $188M x 11.1x
LMAT ██% $2.26B 36.2x 5.6x
LNSR ██% $65M 2.2x 6.0x
LUCD ██% $172M x 43.1x
LUNG ██% $52M x 1.1x
LYRA ██% $890K x x
MBOT ██% $117M x 1.6x
MCAG ██% $37M x x
MDAI ██% $52M x x
MDLN ██% $70.74B 84.5x 6.3x
MDNC ██% $59M 65.1x 10.0x
MDXG ██% $634M 20.7x 2.6x
MMED ██% $4.59B x 1.3x
MMM ██% $87.46B 29.2x 29.6x
MMSI ██% $4.54B 32.6x 2.8x
MODD ██% $12M x 1.0x
NEPH ██% $37M 47.9x 3.5x
NMTC ██% $16M x 3.1x
NPCE ██% $498M x 34.4x
NSPR ██% $32M x 0.7x
NUMD ██% $2M x x
NVCR ██% $2.32B x 6.9x
NVNO ██% $7M x 0.3x
NXGL ██% $4M x 1.0x
NYXH ██% $147M x x
OBIO ██% $213M x 5.2x
ODYY ██% $710K x x
OFIX ██% $443M x 1.0x
OSRH ██% $15M x 0.1x
OSUR ██% $280M x 0.9x
PAVM ██% $32M x 0.8x
PDEX ██% $175M 14.6x 3.9x
PEN ██% $12.49B 73.0x 8.5x
PETV ██% $25M x 11.4x
PFSA ██% $930K x x
PLRZ ██% $29M x 1.1x
PLSE ██% $2.11B x 31.9x
PMI ██% $9M x 2.4x
PODD ██% $11.08B 36.6x 8.5x
PRCT ██% $999M x 2.9x
PREM ██% $2M x 0.6x
PROF ██% $249M x 4.2x
PSTV ██% $26M x 2.2x
PYPD ██% $77M x 7.0x
QTEX ██% $49M x 21.3x
RCEL ██% $142M x x
RDGL ██% $29M x 10.7x
RMD ██% $27.83B 18.3x 4.3x
RTGN ██% $75M x x
RVP ██% $20M x 0.3x
SGHT ██% $254M x 4.7x
SGP ██% $698M x 2.8x
SIBN ██% $728M x 4.1x
SIGY ██% $160K x x
SINT ██% $9M x 10.2x
SKIN ██% $95M x 1.7x
SNOA ██% $6M x 1.8x
SNWV ██% $51M 3.2x 27.7x
SOLV ██% $13.85B 9.7x 2.8x
SRTS ██% $50M x 1.1x
SSII ██% $681M x 12.5x
SSKN ██% $0.00M x 0.0x
STIM ██% $121M x 9.1x
STME ██% $6M x x
STVN ██% $5.45B x x
SYK ██% $129.82B 38.9x 5.7x
TCMD ██% $635M 31.3x 2.9x
TELA ██% $27M x x
TFX ██% $5.91B x 1.9x
TLSI ██% $267M x 20.8x
TMCI ██% $258M x 3.4x
TNDM ██% $1.15B x 8.7x
TNON ██% $3M x 1.7x
UFPT ██% $1.89B 27.5x 4.3x
USAQ ██% $5M 10.4x 3.0x
UTMD ██% $217M 20.0x 1.8x
VTAK ██% $1M x 0.1x
VVOS ██% $6M x x
VYCO ██% $2M x x
WST ██% $23.20B 41.1x 7.8x
XAIR ██% $4M x 0.6x
XTNT ██% $60M 33.0x 1.2x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Nuo Therapeutics, Inc. Stock Forecast

How accurate are Nuo Therapeutics, Inc. stock predictions?

Our AI model shows a 20% Spearman correlation coefficient for AURX predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Nuo Therapeutics, Inc. stock price forecasts?

Our analysis considers Nuo Therapeutics, Inc.'s financial metrics, Industrial Applications and Services sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Nuo Therapeutics, Inc. a good investment in 2025?

Based on our AI analysis, Nuo Therapeutics, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Nuo Therapeutics, Inc. forecasts updated?

Nuo Therapeutics, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want a simpler view of Nuo Therapeutics, Inc.?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...